Knoll Pharma has declared a 33% drop in net profits for the year ended November'01. The company has changed its accounting year from December to November year ending. Hence the latest results are not strictly comparable as this year of the company was for a period of 11 months.
Operating Profit (EBDIT)
Operating Profit Margin (%)
Profit before Tax
Profit after Tax/(Loss)
Net profit margin (%)
No. of Shares (eoy) (m)
Diluted Earnings per share*
P/E (at current price)
On an annualised basis however, sales have registered a growth of more than 6%. Operating margins showed a good improvement of 200 basis points. The jump in operating margins was on the back of upward revision of four formulations of Insulin injection in March. Insulin Vial prices have increased by 22% - 25% since then. Insulin is the biggest revenue churner for Knoll where the company has a market share of close to 60%. Other income was on account of sale of mutual fund units of Rs 58 m and dividend received from wholly owned subsidiary.
Knoll Pharma seems to be in a consolidation mood. The company is in the process of taking shareholder permission to sell/divest its manufacturing unit at Pune and for the buyback of its shares. It plans to sell its plant as a going concern. It is proposing buyback of shares at a maximum price of Rs 350 per share. The markets however, seem to have sensed the proposal ahead of time, with the stock price appreciating more than 30% in last two months.
Knoll Pharma has also proposed 100% dividend i.e. Rs 10 per share. The stock currently trades (cum dividend) at Rs 308. Considering, the dividend the stock still trades at 15% discount to the buyback price proposed by the company.The buyback however, is dependent on shareholder's approval.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India. Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: firstname.lastname@example.org. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407